echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Variety of medical insurance negotiations!

    Variety of medical insurance negotiations!

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 6th, the official website of NMPA showed that the listing application (acceptance number: CYHS1900699) of the 4-type generic drug "Milaberon sustained-release tablets" by Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.


    On April 6th, the official website of NMPA showed that the listing application (acceptance number: CYHS1900699) of the 4-type generic drug "Milaberon sustained-release tablets" by Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.


    Mirabegron is the first approved β3 receptor agonist for overactive bladder (OAB), which selectively relaxes the bladder detrusor and promotes urine by acting on β-adrenergic receptors (β-ARs) Storage, thereby increasing the capacity of the bladder and extending the interval between urination, and does not affect the emptying of the bladder.


    In 2020, during medical insurance negotiations, Astellas’s Mirabegron sustained-release tablets were reduced by 69.


    Insight database shows that at present, only the original research of Mirabegron has been approved for marketing in China, and no generic drugs have been approved.


    Source: Insight database (http://db.


    Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.